Tilly, a digital fertility health startup started in 2019 by Anna Sane and Jenny Ann Axson Johnson, has been acquired by Rhea Fertility. Tilly offers infertility sufferers complete treatment tracking and evidence-based mental health resources. Through the purchase, Rhea’s global network of clinics will be able to incorporate evidence-based psychosocial assistance into fertility care.

“Research consistently shows that the emotional toll is one of the primary reasons fertility patients discontinue treatment. Our platform removes barriers to accessing proven support, ensuring that patients receive the care they need throughout their journey,” said Jenny Ann Axson Johnson, Co-Founder of Tilly.

Tilly has been collaborating with fertility clinics across Europe and the U.S., providing digital mental health solutions tailored to fertility patients. Anna Sane, Co-Founder of Tilly, commented, “We have seen the most significant improvements in patient well-being when our tools are seamlessly integrated into the fertility care process. Recognizing the need for greater consolidation in the fertility market, we are thrilled to join Rhea Fertility and contribute to its comprehensive reproductive health ecosystem.”

Margaret Wang, CEO of Rhea Fertility, stated, “We were highly impressed by the platform and content developed by Tilly. As part of our commitment to enhancing the patient experience within our GenPrime clinics, we recognize that psychosocial support is a critical component of the fertility journey.”

The deal comes after Rhea recently acquired Embryonics, a cutting-edge diagnostic tool suite driven by AI. Rhea Labs, a technology-driven platform that uses data and analytics to speed innovation and improve patient results, powers Rhea Fertility’s global network of owned and partner clinics under the GenPrime brand.